Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AttaCH open-label extension of once-weekly TransCon CNP in children and adolescents with achondroplasia
2022-502202-33-00Phase 2Authorised
- Sponsor
- Ascendis Pharma
- Start
- Jul 2023
- Modality
- Peptides, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 15
01
Overview
Phase 2, open-label, single-arm trial of navepegritide in achondroplasia (ACH), sponsored by Ascendis Pharma. Primary endpoints: Incidence of treatment-emergent adverse events and Height Z-scores. Planned start Jul 2023; status: authorised.
02
Drugs
navepegritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on 2022-502202-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502202-33-00.